Coaching program for women on ribociclib and aromatase inhibitor
Part of Cancer clinical trials.
This study tests whether a coaching program based on personality types helps women with early-stage hormone receptor-positive, HER2-negative breast cancer stick to their treatment plan. Participants must be taking ribociclib (Kisqali) and an aromatase inhibitor, and their cancer must not have spread to other organs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with invasive breast cancer that is hormone receptor-positive (ER and/or PR positive) and HER2-negative.
- Your doctor has prescribed ribociclib (Kisqali) combined with an aromatase inhibitor (like letrozole) for early-stage breast cancer.
- You are at least 18 years old and willing to sign a consent form.
- Your cancer has not spread to other organs (stage IV) and you have not had a recurrence after surgery.
- You are generally healthy (no serious infections, heart rhythm problems, or allergies to ribociclib or its ingredients like peanuts or soy).
- If you could become pregnant, you must agree to use highly effective birth control and have a negative pregnancy test.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether supporting patients helps them stick to their prescribed oral breast cancer treatment (abemaciclib and hormone therapy). If you're already taking this combination for early-stage breast cancer, the study team may provide extra guidance to help you stay on track.
This study observes people with early-stage hormone receptor positive, HER2-negative breast cancer who are taking ribociclib (Kisqali) with hormone therapy after surgery. It aims to see how well the treatment works and how safe it is in real life.
This trial looks at how well ribociclib works and why it may stop working over time in people with advanced, hormone-receptor–positive, HER2-negative breast cancer. It also analyzes blood and tissue samples to help researchers understand resistance patterns and improve future treatment decisions.
This study looks at how well a combination of two medicines (a CDK4/6 inhibitor and an aromatase inhibitor) works for people with a certain type of advanced breast cancer. It aims to gather real-world information to better understand treatment patterns and outcomes.
This trial checks how well people stick to their prescribed ribociclib (Kisqali) plus aromatase inhibitor treatment for early-stage, hormone-receptor-positive, HER2-negative breast cancer, and monitors for side effects. It focuses on making sure patients are safe and supported while taking their medication.
This trial tests ribociclib, a targeted therapy, for women with hormone receptor-positive, HER2-negative breast cancer who still have cancer cells in the breast or lymph nodes after initial chemotherapy. It aims to reduce the chance of cancer coming back.
Hear when a new HR+/HER2- Early Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.